Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

cts in clinical development or marketed products.

There can be no assurance that we will conduct additional CMV studies in the future. The FDA or other regulatory authorities may prohibit any future studies with maribavir or alternatively may require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval. There can be no guarantee that we will be successful in gaining regulatory approval of maribavir for any indications. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a competing product which has been granted orphan drug designation thereby preventing Cinryze from reaching the market for acute treatment of HAE. There can be no assurance that the FDA or EMEA will not require additional or unanticipated studies or clinical trial outcomes before granting regulatory approval of any of our product candidates, or that we will be successful in gaining regulatory approval of any of our product candidates. Currently our market capitalization is less than our book value. As a result, we may be required to take a significant non-cash goodwill impairment charge and may be required to write off goodwill or other intangible assets in the future. If we are required to write off goodwill or other intangible assets, our financial position or resu
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Beckman Coulter,Inc. (NYSE: BEC ), a ... automate, and innovate complex biomedical testing,announced today that ... Business Development, will present at the following,conferences:, ... -- Bank of America 2008 Healthcare Conference on ...
... in physician,s office -, MADISON, N.J., May ... Diagnostics Incorporated (NYSE: DGX ),today announced the ... fecal,immunochemical test, a point-of-care version of the company,s ... sensitivity and,specificity of the laboratory-based InSure FIT test., ...
... CE Mark Approval for First Product, the CorMatrix ... ECM(TM) for Pericardial ... based company dedicated to developing and delivering unique,extracellular matrix (ECM(TM)) ... cardiovascular tissue, announced,today that the company has received 510(k) clearance ...
Cached Biology Technology:Beckman Coulter to Present at Upcoming Healthcare Conferences 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 3Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 4Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 5CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 2CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 3CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 4
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... of funding-- dollars drop, in this particular case, for ... faculty and staff. Those declines ultimately impact student ... "Obviously if you,ve had a 30% reduction in funding, ... budget. And so programs are affected," says Colorado ...
... − A new study from the Infant Brain Imaging ... Research at the Children,s Hospital of Philadelphia (CHOP), found ... months in high-risk infants who later develop autism, compared ... "It,s a tremendously exciting finding," said Sarah Paterson, PhD, ...
... SEATTLE Evolutionary biologist Harmit Singh Malik, Ph.D., of ... grant from the Lupus Research Institute to study the ... lupus, an autoimmune disease. , Malik and colleagues want ... causes lupus autoimmunity., "We want to determine whether autoimmunity ...
Cached Biology News:New autism research reveals brain differences at 6 months in infants who develop autism 2Did an evolutionary arms race cause lupus? Biologist Harmit Malik receives grant to try and find out 2
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... instrument engineered to match the speed of ... of research centers worldwide. It uses 1.5 ... ideally suited for high-speed temperature cycling due ... surface-area-to-volume ratio. ,By combining glass capillary tubes ...
... CUL-3 is a member of the family of human ... homologous to the S. cerevisiae cdc53 gene. Cullin-3 is ... It forms a tight complex with cyclin E and ... by protesomes. Cyclin E is an activator of cdk2, ...
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
Biology Products: